These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32566037)

  • 21. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
    Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
    Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy.
    Morinaga S; Nakamura Y; Atsumi Y; Murakawa M; Yamaoku K; Aoyama T; Kobayashi S; Ueno M; Morimoto M; Yokose T; Miyagi Y
    Anticancer Res; 2016 Mar; 36(3):1083-8. PubMed ID: 26977002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
    Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
    J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
    Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
    Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
    Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
    World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
    Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
    Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
    Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
    World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer.
    Chen Y; Kang M; Lu W; Guo Q; Zhang B; Xie Q; Wu Y
    J Cancer Res Clin Oncol; 2012 Sep; 138(9):1463-74. PubMed ID: 22526154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
    Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
    Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells.
    Takiuchi D; Eguchi H; Nagano H; Iwagami Y; Tomimaru Y; Wada H; Kawamoto K; Kobayashi S; Marubashi S; Tanemura M; Mori M; Doki Y
    Pancreatology; 2013; 13(5):517-23. PubMed ID: 24075517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.
    Takahashi R; Ijichi H; Sano M; Miyabayashi K; Mohri D; Kim J; Kimura G; Nakatsuka T; Fujiwara H; Yamamoto K; Kudo Y; Tanaka Y; Tateishi K; Nakai Y; Morishita Y; Soma K; Takeda N; Moses HL; Isayama H; Koike K
    Sci Rep; 2020 Dec; 10(1):21194. PubMed ID: 33273652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.
    Moriyama T; Ohuchida K; Mizumoto K; Yu J; Sato N; Nabae T; Takahata S; Toma H; Nagai E; Tanaka M
    Mol Cancer Ther; 2009 May; 8(5):1067-74. PubMed ID: 19435867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
    Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
    World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
    Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
    Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.
    Parasramka MA; Ali S; Banerjee S; Deryavoush T; Sarkar FH; Gupta S
    Mol Nutr Food Res; 2013 Feb; 57(2):235-48. PubMed ID: 23293055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.